Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study

The study aim was to evaluate the efficacy of adalimumab (ADA) in a large series of Behçet’s disease (BD)-related uveitis. We performed a multicenter retrospective observational study including 40 selected patients (66 eyes) receiving ADA. Clinical data were retrospectively analyzed at baseline, at...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2017, Vol.36 (1), p.183-189
Main Authors: Fabiani, Claudia, Vitale, Antonio, Emmi, Giacomo, Vannozzi, Lorenzo, Lopalco, Giuseppe, Guerriero, Silvana, Orlando, Ida, Franceschini, Rossella, Bacherini, Daniela, Cimino, Luca, Soriano, Alessandra, Frediani, Bruno, Galeazzi, Mauro, Iannone, Florenzo, Tosi, Gian Marco, Salvarani, Carlo, Cantarini, Luca
Format: Article
Language:English
Subjects:
Adalimumab - administration & dosage
Adult
Antirheumatic Agents - administration & dosage
Behcet Syndrome - complications
Behcet Syndrome - drug therapy
Female
Humans
Inflammation
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Patient Safety
Retrospective Studies
Rheumatology
Tomography, Optical Coherence
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Uveitis - complications
Uveitis - drug therapy
Vasculitis - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aim was to evaluate the efficacy of adalimumab (ADA) in a large series of Behçet’s disease (BD)-related uveitis. We performed a multicenter retrospective observational study including 40 selected patients (66 eyes) receiving ADA. Clinical data were retrospectively analyzed at baseline, at 3 and 12 months of treatment. Primary end point was reduction of ocular inflammatory flares. Secondary end points were improvement of best corrected visual acuity (BCVA), reduction of macular thickness measured by optical coherence tomography (OCT), reduction in the occurrence of vasculitis assessed by fluorescein angiography (FA), and evaluation of statistically significant differences between patients treated with ADA monotherapy and those undergoing ADA plus DMARDs and in patients firstly treated with ADA compared to patients previously administered with other biologics; ADA steroid sparing effect was also evaluated. During the first 12 months of ADA therapy, the number of flares significantly decreased from 200 flares/100 patients/year to 8.5 flares/100 patients/year ( p  
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-016-3480-x